Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AVTR 
Avantor Inc (AVTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: AVTR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $16.92
1 Year Target Price $16.92
| 6 | Strong Buy |
| 4 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.79% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.49B USD | Price to earnings Ratio 13.38 | 1Y Target Price 16.92 |
Price to earnings Ratio 13.38 | 1Y Target Price 16.92 | ||
Volume (30-day avg) 21 | Beta 1.05 | 52 Weeks Range 11.82 - 28.00 | Updated Date 07/2/2025 |
52 Weeks Range 11.82 - 28.00 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.7% | Operating Margin (TTM) 8.21% |
Management Effectiveness
Return on Assets (TTM) 3.53% | Return on Equity (TTM) 12.52% |
Valuation
Trailing PE 13.38 | Forward PE 13.07 | Enterprise Value 12963043263 | Price to Sales(TTM) 1.42 |
Enterprise Value 12963043263 | Price to Sales(TTM) 1.42 | ||
Enterprise Value to Revenue 1.94 | Enterprise Value to EBITDA 8.87 | Shares Outstanding 681430016 | Shares Floating 663855592 |
Shares Outstanding 681430016 | Shares Floating 663855592 | ||
Percent Insiders 1.35 | Percent Institutions 103.17 |
Upturn AI SWOT
Avantor Inc
Company Overview
History and Background
Avantor, Inc. was founded in 1904 as J.T. Baker Chemical Company. It evolved through various acquisitions and mergers, becoming a leading provider of products and services to the life sciences and advanced technologies industries.
Core Business Areas
- Materials and Consumables: Offers a broad range of high-purity chemicals, reagents, labware, filtration products, single-use solutions, and other consumables for research, development, and production.
- Services and Equipment: Provides services such as lab support, equipment maintenance and repair, instrument calibration, and custom manufacturing solutions. It also distributes analytical instruments and other laboratory equipment.
Leadership and Structure
Avantor is led by a CEO and a senior management team overseeing its global operations. The organizational structure includes business units focused on specific customer segments and product categories.
Top Products and Market Share
Key Offerings
- High-Purity Chemicals and Reagents: Essential for research, development, and manufacturing processes across various industries. Market share fluctuates but is estimated to be around 15-20% in specialized segments. Competitors include Merck KGaA and Thermo Fisher Scientific. Revenue for this segment is significant, accounting for a large portion of Avantoru2019s materials and consumables segment. Users include researchers, scientists, and manufacturers.
- Single-Use Solutions: Used in biopharmaceutical manufacturing to eliminate the need for cleaning and sterilization. This market is growing rapidly. Competitors include Sartorius Stedim Biotech and Danaher Corporation (Cytiva). Market share estimates vary based on specific product types. Revenue for this sector is a significant area of growth for Avantor. Users are pharmaceutical companies.
Market Dynamics
Industry Overview
The life sciences and advanced technologies industries are driven by research, development, and manufacturing activities. Key trends include increasing demand for biopharmaceuticals, personalized medicine, and advanced materials.
Positioning
Avantor is positioned as a key supplier of high-quality materials, consumables, and services to these industries. Its competitive advantages include a broad product portfolio, global reach, and strong customer relationships.
Total Addressable Market (TAM)
The total addressable market for Avantor's products and services is estimated to be in the hundreds of billions of dollars globally. Avantor is positioned to capture a portion of this market through its diverse offerings and geographic reach.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global reach and distribution network
- Strong customer relationships
- Focus on high-quality products and services
- Established brand reputation
Weaknesses
- Exposure to economic cycles
- Dependence on key suppliers
- Integration risks from acquisitions
- Complexity of managing a large, diverse organization
Opportunities
- Growing demand for biopharmaceuticals
- Expanding into emerging markets
- Developing new and innovative products
- Acquiring complementary businesses
- Offering value added services
Threats
- Increased competition
- Pricing pressures
- Regulatory changes
- Disruptions in supply chain
- Economic downturns
Competitors and Market Share
Key Competitors
- TMO
- DHR
- MRK
Competitive Landscape
Avantor competes with larger players in the life sciences industry. It differentiates itself through its focus on high-purity materials, consumables, and value added services.
Major Acquisitions
Masterflex Bioreactors
- Year: 2021
- Acquisition Price (USD millions): 2100
- Strategic Rationale: To expand Avantoru2019s single-use bioprocessing portfolio.
Growth Trajectory and Initiatives
Historical Growth: Avantor has experienced growth through acquisitions and organic expansion. Data should be retrieved from a financial data provider.
Future Projections: Analysts project continued growth for Avantor, driven by demand in the life sciences and advanced technologies industries. Data should be retrieved from a financial data provider.
Recent Initiatives: Recent initiatives include acquisitions to expand its product portfolio and investments in new technologies.
Summary
Avantor is a key supplier in the life sciences and advanced technologies industries, driven by its wide-ranging portfolio and global network. The lack of dividends may deter some investors. Strategic acquisitions have boosted growth, but integration is crucial. Threats from increased competition and economic shifts are something to monitor.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data should be independently verified.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avantor Inc
Exchange NYSE | Headquaters Radnor, PA, United States | ||
IPO Launch date 2019-05-17 | President, CEO & Director Mr. Michael Stubblefield | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.avantorsciences.com |
Full time employees 13500 | Website https://www.avantorsciences.com | ||
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.